The European Commission has launched a pilot program to simplify the approval process for certain clinical studies conducted across multiple European Union (EU) countries. The initiative aims to streamline applications, allowing sponsors to submit a single request for coordinated assessment.
By centralizing interactions with national authorities, the program seeks to create a more predictable process for approvals. It is designed to reduce administrative burdens, improve communication between countries, and ensure greater consistency in decision-making.
Sponsors can engage with all participating EU states simultaneously, avoiding delays caused by differing national interpretations. The program also aims to standardize requests for additional information, making the process more efficient.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze